Cost-Effectiveness of Early Treatment With Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients With Established Rheumatoid Arthritis

Advances in Therapy - United States
doi 10.1007/s12325-019-00986-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC


Related search